Hints and tips:
Related Special Reports
...In 1995, the trust divested itself of any interest in pharmaceuticals by selling all remaining stock to Glaxo plc....
...The drugs used were developed by the Wellcome Foundation and Glaxo Laboratories, both now part of UK-listed GSK, which posted £22bn in turnover in the first nine months of last year....
...The companies said UKCM’s board was “minded to recommend” the deal to shareholders “excluding” chair Peter Pereira Gray, a former head of the investment division for the Wellcome Trust, who is not backing...
...It was under his successor, Sir Richard Sykes, that Glaxo undertook two major transactions — acquiring Wellcome in 1995 and merging with SmithKline Beecham in 2000 — which radically altered the portfolio...
...Glaxo first bought Wellcome in 1995 and then SmithKline Beecham in 2000, becoming GSK. Glencore acquired Xstrata in 2013....
...*This article has been amended since original publication to clarify the statements of the Wellcome Trust....
...Most investment in London has targeted the so-called “knowledge quarter” around King’s Cross, which includes University College Hospital, the Crick Institute, the Wellcome Trust and several universities....
...Wellcome had its most successful financial year in 2021 since when the trust publicly sold its last remaining shares to Glaxo Plc in 1995 to form the world’s largest pharmaceutical company Glaxo Wellcome...
...Groups including Microsoft have trialled the shorter week, although the UK’s Wellcome Trust in 2019 cancelled plans for a pilot, saying it had proved “too operationally complex”....
...It used to be a game to slip one into your pocket or handbag to take pride of place in your home.The Wellcome Collection has a picture in its library of the last one left in the building in 2007, the day...
...Sir Jeremy Farrar, director of the Wellcome Trust medical charity and a member of the government’s Sage advisory committee, told the Financial Times that this year was “very unpredictable” as new viral variants...
...Still, results this month from large listed British companies have started to show how broad the impact of sustained higher prices will be on UK plc....
...Research charity Wellcome concluded the switch was “too operationally complex”. British bosses have never come on board, fretting that shorter working weeks could leave a puddle of red ink....
...France is the most vaccine-hesitant country in the world, according to a 2018 Gallup-Wellcome Trust study....
...The Wellcome Trust estimates that not until 2023 or 2024 will everyone who needs a vaccine be able to receive one....
...In London last year, the Wellcome Trust biomedical research foundation concluded it could not even conduct a trial of the four-day week without “an unacceptable disruption” to its business....
...Wellcome (now GSK), British Telecom and British Aerospace (now BAE Systems)....
...However, there is also substantial opposition to vaccines in other high-income countries which are likely to be more sceptical about the safety of immunisations, according to a recent study by the Wellcome...
...Charlie Weller, head of vaccines at Wellcome, said: “The preliminary results from the Oxford/AstraZeneca team are hugely encouraging....
...Jeremy Farrar, director of the Wellcome Trust, said: “It is very unusual to go through a vaccine trial and not to pause it.”...
...Industry is stepping up, with the WHO, European Investment Bank and Wellcome Trust, to bring two to four novel antibiotics to patients by 2030....
...Jeremy Farrar, director of the Wellcome Trust, a research charity based in London, said: “It’s very unusual to go through a vaccine trial and not to have to pause it.”...
...Some say having ex Goldman banker and Glaxo finance director Dingemans as chair, with former HMRC “big beast” Thompson as chief exec, was asking for a turf war....
...Fellow Sage member Sir Jeremy Farrar, director of the Wellcome Trust agreed with Prof Edmunds on Twitter. “Covid-19 spreading too fast to lift lockdown in England....
...seen whether his ambitious “five-pillar” plan — engaging the private sector in testing and trying to develop a “huge diagnostic industry” almost from scratch involving big companies like AstraZeneca and Glaxo...
International Edition